DexCom Inc (DXCM)

70.04
0.58 0.84
NASDAQ : Health Care
Prev Close 69.46
Open 69.28
Day Low/High 68.92 / 69.87
52 Wk Low/High 47.92 / 103.29
Volume 527.98K
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 86.56M
Market Cap 6.00B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Fitbit And Dexcom To Develop Continuous Glucose Monitoring (CGM) Experience For People Living With Diabetes

Fitbit And Dexcom To Develop Continuous Glucose Monitoring (CGM) Experience For People Living With Diabetes

Fitbit (NYSE:FIT), the leading global wearables brand, and DexCom, Inc.

New Study Shows People With Type 2 Diabetes Benefit From Continuous Glucose Monitoring

New Study Shows People With Type 2 Diabetes Benefit From Continuous Glucose Monitoring

DexCom, Inc. (Nasdaq: DXCM), announced today the publication of a new study that shows people with Type 2 diabetes on a multiple daily injection (MDI) insulin therapy benefit from the use of continuous glucose monitoring...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BETR, CG, DXCM, ITG, JLL, KEM, NUS, STRL, SUM, SWIR Downgrades: DVA, GHC, ISCA, QRVO, RDC, SCMP Initiations: ASPU Read on to get TheStreet Quant Ratings' detailed report:

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Matthew Dolan, VP Corporate Development, will present an update on the...

DexCom, Inc. Reports Second Quarter 2017 Financial Results

DexCom, Inc. Reports Second Quarter 2017 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended June 30, 2017.

DexCom Announces Upcoming Conference Presentation

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and Corporate...

DexCom Schedules Second Quarter 2017 Earnings Release And Conference Call For August 1, 2017 At 4:30 P.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2017 financial results after market close on Tuesday, August 1, 2017.

Apple Watch Is on Its Way to Becoming a $6 Billion Business, but Is That Really Enough?

Apple Watch Is on Its Way to Becoming a $6 Billion Business, but Is That Really Enough?

After a slump early last year, the smartwatch's sales have been rebounding.

New Study Shows Adults With Type 1 And Type 2 Diabetes On Multiple Daily Injections (MDI) Benefit From CGM

DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, is presenting important clinical data for patients with type 1 and type 2 diabetes, at the American Diabetes...

Dexcom To Add Ambulatory Glucose Profile (AGP) To Dexcom CLARITY®

DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, announced today that it incorporated Ambulatory Glucose Profile (AGP) into its Dexcom CLARITY software.

DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices

DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices

DexCom's app tracks glucose levels for people with diabetes.

DexCom Announces FDA Approval Of G5 Mobile App For Android Devices

DexCom, Inc. (Nasdaq: DXCM) the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce the Food and Drug Administration (FDA) approval of the Dexcom G5 mobile app for Android...

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

After a slump early last year, the smartwatch's sales have been rebounding. New features unveiled at Apple's WWDC conference could aid its momentum later this year.

DexCom Stock Surging on Apple Watch Partnership

DexCom Stock Surging on Apple Watch Partnership

Apple will release a new Bluetooth API for the Apple Watch.

Markets Down? Get Used to It: Cramer's 'Mad Money' Recap (Wednesday 5/17/17)

Markets Down? Get Used to It: Cramer's 'Mad Money' Recap (Wednesday 5/17/17)

First serious down day in ages? Jim Cramer says it's as normal as rain; and he has an umbrella for you.

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: Kevin Sayer, President & Chief Executive Officer, will present on...

DexCom Prices Offering Of $350 Million Of 0.75% Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) ("DexCom") announced today the pricing of its offering of $350 million aggregate principal amount of 0.

DexCom Announces Proposed Offering Of $300 Million Of Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) ("DexCom") announced today that it intends to offer, subject to market conditions and other factors, $300 million aggregate principal amount of Convertible Senior Notes due 2022 (the "notes") in...

DexCom, Inc. Reports First Quarter 2017 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended March 31, 2017.

10 Things We Learned From Our Daily Facebook Show With Jim Cramer

10 Things We Learned From Our Daily Facebook Show With Jim Cramer

A few important takeaways from our daily Facebook show with Jim Cramer.

Jim Cramer: Report of Apple's Diabetes Test Isn't a Reason to Own the Stock

Jim Cramer: Report of Apple's Diabetes Test Isn't a Reason to Own the Stock

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said reports of Apple developing a diabetes testing product is not a reason to own the stock.

Trader's Daily Notebook: Worried About Volume? Just Let It Go

Trader's Daily Notebook: Worried About Volume? Just Let It Go

Old-line momentum favorites fare well.

Trader's Daily Notebook: Worried About Volume? Just Let It Go

Trader's Daily Notebook: Worried About Volume? Just Let It Go

Old-line momentum favorites fare well.

Medicare Announces Criteria Covering Dexcom G5 Mobile CGM For All People With Diabetes On Intensive Insulin Therapy

DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce that the U.

DexCom Schedules First Quarter 2017 Earnings Release And Conference Call For May 2, 2017 At 4:30 P.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2017 financial results after market close on Tuesday, May 2, 2017.

When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)

When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)

Jim Cramer says economic fundamentals remain strong and this market's rallying with relief at Fed's anticipated rate hike.

DexCom Appoints Richard Collins To Board Of Directors

DexCom, Inc. (Nasdaq: DXCM) today announced that Richard Collins has been appointed to the company's Board of Directors, effective March 9, 2017.

DexCom, Inc. Reports Fourth Quarter And Fiscal Year 2016 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2016.

TheStreet Quant Rating: C- (Hold)